Seelos Therapeutics Reports Q3 2019 Pipeline Update

Written by Customer Service on . Posted in Public Companies.

NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) — Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company, today released its third quarter pipeline update.Seelos received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Seelos’ U.S. Patent Application for SLS-005 (trehalose) for treating Friedreich Ataxia (FA).The company received a grant from Team Sanfilippo Foundation for funding of studies of SLS-005 in Sanfilippo syndrome type A and B patients and the separate expanded access study for Sanfilippo type C and D as well as type A and B patients who do not meet the trial entry criteria.Seelos announced the Investigational New Drug Submission and Acceptance from FDA for SLS-005 for Mucopolysaccharidosis type III (Sanfilippo syndrome).The Seelos staff and board of directors rang the opening bell at the Nasdaq Marketsite in Times Square on August 12th.The company raised $6.7 million in a registered direct offering with certain institutional investors.Update on Pipeline Development
Seelos is initiating its Phase I studies to further evaluate the pharmacokinetics (PK), pharmacodynamics (PD), and drug-drug interactions (DDI) of SLS-002 (intranasal racemic ketamine) in healthy volunteers this quarter and preliminary data from such studies are expected in Q1 2020.Seelos amended its agreement with Vyera Pharmaceuticals which removes the requirement to conduct a Phase III trial for SLS-002 and converts the one-time cash payment obligation otherwise owed to Vyera for commencement of the Phase III trial to a series a cash and stock payments over the next 9 months.The company completed a Type C meeting (face to face) with the FDA to discuss the potential design of a Proof of Concept (PoC) study for SLS-002. Based on feedback from its Type C meeting with FDA, Seelos plans to conduct a Phase II PoC study in patients with Major Depressive Disorder (MDD) at Imminent Risk of Suicide.The company is seeking scientific advice from EMA to initiate a clinical study in Sanfilippo syndrome patients in EU.
 Seelos began IND enabling work this quarter on SLS-008 which it plans to develop for pediatric esophagitis, an orphan disease and is exploring other potential target indications.Forward-Looking Statements

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.